Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.43    -0.02 (-0.45%)
Bid:
4.355
Ask:
4.45
Spread: 0.095 (2.181%)
Market Cap: £212.62m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Ambarella & Seeing Machines Collaboration

6 Jan 2022 10:01

RNS Number : 6359X
Seeing Machines Limited
06 January 2022
 

PRESS RELEASE

 

 

Seeing Machines and Ambarella collaborate on integrated forward-facing ADAS and in-cabin occupant and driver monitoring system solutions

 

CANBERRA, Australia and SANTA CLARA, Calif. - Jan. 6, 2022 - Seeing Machines Limited (LSE: SEE), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, announced a collaboration with Ambarella, Inc. (NASDAQ: AMBA), an AI vision silicon company, to bring integrated Advanced Driver Assistance System (ADAS) and occupant and driver monitoring system (OMS and DMS) solutions to the market.

 

This unique technology combination will bring Seeing Machines' industry leading OMS and DMS technology solutions to Ambarella's CV2x CVflow® family of edge AI perception systems on chip (SoCs). Ambarella's CV2x-based reference design platform performs the vision processing and fusion of Seeing Machines' driver monitoring software with forward-facing ADAS features to provide a complete, integrated DMS and ADAS solution.

 

Ambarella's SoCs target both standalone and integrated DMS, OMS and forward-facing ADAS cameras. As part of this collaboration, Seeing Machines will enable its embedded Driver Monitoring Engine (e-DME) software to provide a highly optimized, accelerated "back end." This e-DME back end will utilize the CVflow acceleration engine inside Ambarella's SoCs, allowing forward-facing ADAS camera designers to seamlessly integrate Seeing Machines' proven OMS and DMS technology.

 

This agreement marks the beginning of a strategic relationship where Ambarella and Seeing Machines intend to combine their skills, products, IP and experience in the domain of embedding AI vision algorithms to deliver best-in-class driver and occupant monitoring system solutions.

 

Paul McGlone, CEO at Seeing Machines commented: "The contextual information that can be gathered with the fusion of inward and outward facing sensing is an important area for us as we seek to advance our safety focused technology solutions. Ambarella has made significant advances in forward-facing sensing, with its recent Oculii radar technology acquisition and its collaborations in the algorithm space, to make this a really interesting opportunity for Seeing Machines.

 

"The Ambarella reference design platform, targeting the headliner location, is a key integration point for DMS/OMS technology in both the processing and sensor space. We are excited to work towards offering our e-DME targeting Ambarella's silicon and to also work closely on the fusion of our technology with companies focusing on external vehicle sensing."

 

Fermi Wang, President and CEO at Ambarella commented: "Ambarella's partnership with Seeing Machines, the leader of in-cabin monitoring solutions, offers our customers the most advanced forward-facing ADAS camera plus DMS solutions. Leveraging the industry leading performance per watt of our CVflow AI perception SoCs and Seeing Machines' sophisticated AI-based driver and occupant monitoring algorithms will enable automotive safety systems with the very highest levels of accuracy and reliability."

 

About Seeing Machines (LSE: SEE), a global company founded in 2000 and headquartered in Australia, is an industry leader in vision-based monitoring technology that enable machines to see, understand and assist people. Seeing Machines' technology portfolio of AI algorithms, embedded processing and optics, power products that need to deliver reliable real-time understanding of vehicle operators. The technology spans the critical measurement of where a driver is looking, through to classification of their cognitive state as it applies to accident risk. Reliable "driver state" measurement is the end-goal of Driver Monitoring Systems (DMS) technology. Seeing Machines develops DMS technology to drive safety for Automotive, Commercial Fleet, Off-road and Aviation. The company has offices in Australia, USA, Europe and Asia, and supplies technology solutions and services to industry leaders in each market vertical. www.seeingmachines.com

 

About Ambarella

Ambarella's products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving and robotics applications. Ambarella's low-power systems on chip (SoCs) offer high-resolution video compression, advanced image processing and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com

Seeing Machines Contact:

· Sophie Nicoll, sophie.nicoll@seeingmachines.com, +61 419-149-683

 

Ambarella Contacts:

· Media contact: Eric Lawson, elawson@ambarella.com, +1 480-276-9572

· Investor contact: Louis Gerhardy, lgerhardy@ambarella.com, +1 408-636-2310

· Sales contact: www.ambarella.com/about/contact/inquiries

Stifel Nicolaus Europe Limited (Nomad and Sole Broker - Seeing Machines) Contacts:

Alex Price / Nick Adams: +44 20 7710 7600

 

All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications, and pricing at any time without notice.

 

# # #

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBFMPTMTBMMPT
Date   Source Headline
7th Aug 20097:00 amRNSAppointment of broker
11th Jun 20099:12 amRNSDirector/PDMR Shareholding
21st May 20097:58 amRNSDirector Shareholding
11th Mar 20097:00 amRNSReviewed Interim Results
18th Feb 20097:00 amRNSRestructuring of the business
28th Jan 20099:41 amRNSTrading update and notice of results
1st Dec 20088:14 amRNSChange of Registered Office
27th Nov 20088:08 amRNSResult of AGM
29th Oct 200810:52 amRNSNotice of AGM
23rd Sep 20087:00 amRNSFinal Results
17th Sep 20088:37 amRNSNotice of Final Results
26th Aug 20088:33 amRNSNEW FACEAPI PRODUCT RELEASE
23rd Jul 20087:37 amRNSFirst Expected Profit Report
7th May 20088:08 amRNSNORTH AMERICAN OPERATION
7th Apr 200812:00 pmRNSChange of Broker
4th Mar 20087:59 amRNSInterim Results
4th Mar 20087:51 amRNSMajor contract gain
13th Feb 20088:27 amRNSHolding in Company
28th Dec 20079:11 amRNSAnnual Report
11th Dec 200710:54 amRNSChange of Adviser
29th Nov 200710:03 amRNSAGM Results
8th Nov 200712:38 pmRNSDirector/PDMR Shareholding
8th Nov 200712:34 pmRNSGlaucoma Device at AAO
31st Oct 20079:26 amRNSCompletion of Placing-Replace
31st Oct 20077:01 amRNSCompletion of Placing
26th Oct 20079:35 amRNSShareholder Approval
17th Oct 20072:21 pmRNSDirector/PDMR Shareholding
15th Oct 20079:23 amRNSCFO Appointment
25th Sep 200710:23 amRNSFurther Placing
24th Sep 20071:12 pmRNSFinal Results
24th Sep 20071:00 pmRNSFundraising
15th Aug 200712:43 pmRNSAIM Rule 26 Compliance
15th Aug 20079:27 amRNSFDA Approval for Truefield
2nd Jul 20077:01 amRNSNew Product Releases
29th Jun 200710:11 amRNSMaster License Agreement
22nd May 200711:15 amRNSLicensing agreement signed
8th May 20077:02 amRNSGlaucoma Device Demonstrated
28th Mar 20072:40 pmRNSInterim Results
14th Mar 200710:45 amRNSAward win for glaucoma device
12th Mar 20077:02 amRNSAddition to product released
19th Dec 200610:06 amRNSTotal Voting Rights
30th Nov 20068:27 amRNSAGM Statement
9th Nov 20067:01 amRNSGlaucoma Study Re-commences
2nd Nov 20067:01 amRNSNew Product
19th Oct 20065:38 pmRNSFinal Results - Replacement
19th Oct 200611:29 amRNSFinal Results
18th Oct 200611:04 amRNSDirectorate Change
17th Oct 20063:20 pmRNSNew Version of faceLAB
21st Sep 20064:41 pmRNSIssue of Equity
18th Sep 200611:24 amRNSAutomotive progress

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.